Levels of 17beta-Hydroxysteroid Dehydrogenase Type 10 in Cerebrospinal Fluid of People with Mild Cognitive Impairment and Various Types of Dementias

0447834 - ÚI 2016 RIV NL eng J - Journal Article
Krištofíková, Z. - Říčný, J. - Vyhnálek, M. - Hort, J. - Laczó, J. - Šírová, J. - Klaschka, Jan - Řípová, D.
Levels of 17beta-Hydroxysteroid Dehydrogenase Type 10 in Cerebrospinal Fluid of People with Mild Cognitive Impairment and Various Types of Dementias.
Journal of Alzheimer's Disease. Roč. 48, č. 1 (2015), s. 105-114. ISSN 1387-2877. E-ISSN 1875-8908
R&D Projects: GA ČR(CZ) GBP304/12/G069
Grant - others:GA MŠk(CZ) ED2.1.00/03.0078; Prague Psychiatric Center(CZ) MH CZ–DRO: 00023752
Institutional support: RVO:67985807
Keywords : 17beta-HSD10 * Alzheimer’s disease * amyloid-beta peptides * biomarker * cerebrospinal fluid
Subject RIV: FH - Neurology
Impact factor: 3.920, year: 2015

Background: Overexpression of the mitochondrial enzyme 17 beta-hydroxysteroid dehydrogenase type 10 (17 beta-HSD10, which is also known as the intracellular amyloid-beta peptide (A beta) binding protein) is observed in cortical or hippocampal regions of patients with Alzheimer's disease (AD). It appears that 17 beta-HSD10 may play a role in the pathogenesis of AD. Objective: We investigated the possibility that levels of 17 beta-HSD10 in cerebrospinal fluid could be a prospective biomarker of AD. Methods: We estimated the enzyme levels in 161 people (15 non-demented controls, 52 people with mild cognitive impairment (MCI), 35 people with probable AD, or 59 people with other types of dementia) and compared them with those of A beta(1-42), tau, and phospho-tau. Results: We found significantly higher levels of 17 beta-HSD10 in people with MCI due to AD (to 109.9%), with AD (to 120.0%), or with other types of dementia (to 110.9%) when compared to the control group. The sensitivity of the new biomarker to AD was 80.0%, and the specificity was 73.3% (compared to controls) or 52.5-59.1% (compared to other types of dementia). Results of multiple linear regression and of correlation analysis revealed AD-mediated changes in links between 17 beta-HSD10 and Mini Mental State Examination score. Conclusion: It seems that changes in 17 beta-HSD10 start many years before symptom onset, analogous to those in A beta(1-42), tau, or phospho-tau and that the levels are a relatively highly sensitive but unfortunately less specific biomarker of AD. A role of 17 beta-HSD10 overexpression in AD is discussed.
Permanent Link: http://hdl.handle.net/11104/0249606